RNA – avidity biosciences, inc. (US:NASDAQ)
Stock Stats
News
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $65.00 price target on the stock.
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Form 4 Avidity Biosciences, For: Nov 18 Filed by: McCarthy Teresa
Form 4 Avidity Biosciences, For: Nov 19 Filed by: LEVIN ARTHUR A
Form SC 13G/A Avidity Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G/A Avidity Biosciences, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SC 13G Avidity Biosciences, Filed by: Avoro Capital Advisors LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.